KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Payables (2016 - 2025)

Pfizer (PFE) has disclosed Payables for 17 consecutive years, with $7.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Payables fell 4.77% to $7.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $7.7 billion, a 4.77% decrease, with the full-year FY2025 number at $7.7 billion, down 4.77% from a year prior.
  • Payables was $7.7 billion for Q4 2025 at Pfizer, up from $5.0 billion in the prior quarter.
  • In the past five years, Payables ranged from a high of $9.1 billion in Q4 2022 to a low of $4.1 billion in Q2 2021.
  • A 5-year average of $6.9 billion and a median of $7.2 billion in 2021 define the central range for Payables.
  • Peak YoY movement for Payables: skyrocketed 35.48% in 2022, then tumbled 37.29% in 2023.
  • Pfizer's Payables stood at $7.8 billion in 2021, then grew by 16.42% to $9.1 billion in 2022, then dropped by 0.33% to $9.1 billion in 2023, then fell by 11.14% to $8.1 billion in 2024, then dropped by 4.77% to $7.7 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Payables are $7.7 billion (Q4 2025), $5.0 billion (Q3 2025), and $7.6 billion (Q2 2025).